Explore the gap between orphan drug approval and PBS reimbursement in Australia. All Too Rare examines patient access to rare disease medicines, the benefits of the orphan drug designation, the impact on PBAC outcomes and the complexity of funding pathways. The report benchmarks Australia to international markets to identify opportunities for faster access to innovative medicines.